Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2002 August;93(4) > Minerva Medica 2002 August;93(4):315-22

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

THERAPEUTICAL NOTES   

Minerva Medica 2002 August;93(4):315-22

Copyright © 2002 EDIZIONI MINERVA MEDICA

language: Italian

Long term study on the efficacy and safety of lornoxicam in rheumatoid arthritis

Frizziero L., Focherini M. C., Valentini M., Reta M., Rocchi P.


PDF


Background. To assess the long term safety and therapeutic action of lornoxicam, a new non steroidal anti-inflammatory agent, in rheumatoid arthritis.
Methods. Open trial was carried out on different dosage schedules of lornoxicam (4 or 8 mg bid and 4mg tid) administered for six to twelve months. Patients of both sexes were enrolled, with classical or definite rheumatoid arthritis according to the A.R.A. criteria.
Results. Thirty-four patients (28 F, 6 M) were admitted, mean age (± SD) 53.9±14.2 years, mean duration of illness 9.2±10.7 years. Lornoxicam 8-16 mg/day showed good safety and therapeutic activity in long term treatment. Clinical improvement was limited, but progression of the disease was controlled. No adverse events were complained.
Conclusions. Lornoxicam presented a worth-while therapeutic action and a good tolerability in rheumatoid arthritis long term treatment.

top of page